Collaboration with Therapeutically-Focused CRO Responds to Customer Demand for InForm(TM) ITM Solutions
WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 16, 2009--
Phase Forward (NASDAQ: PFWD), a leading provider of data management
solutions for clinical trials and drug safety, today announced an
agreement with therapeutically-focused global contract research
organization (CRO) INC Research to extend the benefits of its InForm™
Integrated Trial Management (ITM) solution to INC Research’s customers.
INC Research, headquartered in Raleigh, North Carolina, has 24 office
locations worldwide. Its experienced, regionally-based professionals
provide clinical services, data services, late phase services and
therapeutic expertise in the specialty areas of the central nervous
system, oncology and infectious disease, and in innovative pediatric and
women’s health trials. INC Research has developed a proprietary Trusted
Process® that is designed to deliver to its customers predictable,
dependable outcomes and actionable results based on a proven,
metrics-driven methodology.
“The agreement with Phase Forward is further proof of INC’s steadfast
commitment to provide solutions that best meet each customer’s unique
program requirements,” said Alistair Macdonald, executive vice president
of global services, INC Research. “We have seen increasing demand from
our customers for the use of InForm in their trials. The scale and
complexity of many of our customers’ trials demand the robust technology
offered in the InForm ITM solution, making it an excellent electronic
data capture (EDC) option within our suite of data services. To date,
INC Research has experience with over 100 EDC studies, and we are
delighted to be working with Phase Forward as we enhance our breadth and
depth of expertise.”
“As clinical trials continue to grow in number, increase in
sophistication and expand in reach, many companies are turning to CROs,”
said Mike Davies, vice president, global CRO partnerships at Phase
Forward. “The expertise and experience of a CRO like INC Research
provide a valuable advantage in helping customers maximize the benefits
of electronic data capture offered in InForm.”
Phase Forward’s CRO partnership strategy is designed to assist CRO
clients in achieving success in both the short and long term. Its
customized structure and flexible pricing options help CROs of all sizes
to invest in their own capabilities and capitalize on new growth
opportunities. As of the end of 2008, Phase Forward had over 90 CRO
customers across all of its solutions.
About INC Research Inc.
INC Research is a therapeutically focused contract research organization
with a high performance reputation for conducting global clinical
development programs of the highest integrity. Pharmaceutical and
biotechnology companies look to INC Research for a complete range of
customized Phase I through Phase IV programs in therapeutic areas of
specialty, and in innovative pediatric and women’s health trials. The
company’s The Trusted Process® methodology and therapeutic foresight
leads customers to more confident, better-informed drug and device
development decisions. INC Research is headquartered in Raleigh, North
Carolina, with 24 offices and operational in 36 countries. For more
information please visit www.incresearch.com.
About Phase Forward
Phase Forward is a leading provider of integrated data management
solutions for clinical trials and drug safety. The company offers proven
solutions for electronic data capture (InForm™), phase I clinic
automation (LabPas™), clinical data management (Clintrial™), clinical
trials signal detection (CTSD™), strategic pharmacovigilance (Empirica
Signal™) and Signal Management, adverse event reporting (Empirica
Trace™), applied data standards (WebSDM™), Web-integrated interactive
response technologies (Clarix™), and clinical data analysis and
reporting automation and compliance (Waban SCE/CDR, Waban SMS and Waban
LIMS). In addition, the company provides services in the areas of
application implementation, hosting and validation, data integration,
business process optimization, safety data management and industry
standards. Phase Forward’s products and services have been utilized in
over 10,000 clinical trials involving more than 1,000,000 clinical trial
study participants at over 290 organizations and regulatory agencies
worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer
Institute, Eli Lilly, the U.S. Food and Drug Administration,
GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono,
Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble,
Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier,
Tibotec and the U.K. Medicines and Healthcare Products Regulatory
Agency. Additional information about Phase Forward is available at www.phaseforward.com.
Cautionary Statement
Certain statements made in this press release that are not based on
historical information are forward-looking statements which are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. This press release contains express or
implied forward-looking statements relating to, among other things, the
performance and features of Phase Forward’s products and services,
demand for Phase Forward’s products and services, future business and
operations plans of a Phase Forward customer, and the ability of this
Phase Forward’s customers to realize benefits from the use of Phase
Forward’s products and services. These statements are neither promises
nor guarantees, but are subject to a variety of risks and uncertainties,
many of which are beyond Phase Forward's control, which could cause
actual results to differ materially from those contemplated in these
forward-looking statements. In particular, the risks and uncertainties
include, among other things, the ability of Phase Forward’s customers to
realize benefits from the use of its products and services, the
possibility that customers’ needs or plans may change over time, and the
possibility that the level of demand for Phase Forward’s products and
services may vary. Existing and prospective investors are cautioned not
to place undue reliance on these forward-looking statements, which speak
only as of the date hereof. Phase Forward undertakes no obligation to
update or revise the information contained in this press release,
whether as a result of new information, future events or circumstances
or otherwise. For additional disclosure regarding these and other risks
faced by Phase Forward, see the disclosure contained in Phase Forward's
public filings with the Securities and Exchange Commission including,
without limitation, its most recent Annual Report on Form 10-K.
Source: Phase Forward
Phase Forward
Elaine Maynard, 781-902-4371
elaine.maynard@phaseforward.com
or
CHEN
PR, Inc.
Randy Wambold, 781-672-3119
rwambold@chenpr.com
